Currently out of the existing stock ratings of Supawat Thongthip, 10 are a BUY (100%).

Supawat Thongthip

Work Performance Price Targets & Ratings Chart

Analyst Supawat Thongthip, currently employed at TRUIST, has had 8.33% of price targets met with an average potential upside of 1.64%, reached in 4 days on average.

Supawat Thongthip has documented 20 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AVBP, ArriVent BioPharma at 10-Nov-2026.

Wall Street Analyst Supawat Thongthip

Analyst best performing recommendations are on AVBP (ARRIVENT BIOPHARMA).
The best stock recommendation documented was for AVBP (ARRIVENT BIOPHARMA) on 10/7/2026. The price target of $18 was fulfilled within 13 days with a profit of $1.11 (6.57%), with a performance score of 5.06.

Average potential price target upside

IMNM Immunome AVBP ArriVent BioPharma JANX Janux Therapeutics RCUS Arcus Biosciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 31-May-2024

$30

$14.31 (91.20%)

$21

12 days ago
(10-Nov-2026)

3/4 (75%)

$11.35 (60.86%)

563

Hold Since 01-Oct-2026

$23

$7.31 (46.59%)

$24

12 days ago
(10-Nov-2026)

0/2 (0%)

$4.35 (23.32%)

Buy Since 19-Dec-2023

$35

$19.31 (123.07%)

$35

26 days ago
(27-Oct-2026)

2/11 (18.18%)

$16.23 (86.47%)

14

Buy Since 12-Feb-2026

$40

$24.31 (154.94%)

$40

2 months 12 days ago
(10-Sep-2026)

0/3 (0%)

$15.03 (60.19%)

Buy Since 28-May-2026

$38

$22.31 (142.19%)

$37

3 months 10 days ago
(12-Aug-2026)

0/2 (0%)

$10.01 (35.76%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Supawat Thongthip most bullish on?

Potential upside of $24.38 has been obtained for RCUS (ARCUS BIOSCIENCES)

Which stock is Supawat Thongthip most reserved on?

Potential downside of $13.48 has been obtained for AVBP (ARRIVENT BIOPHARMA)

What Year was the first public recommendation made by Supawat Thongthip?

On 2026
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?